X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with GA.
Lead Product(s): GT005
Therapeutic Area: Ophthalmology Product Name: GT005
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $1,500.0 million Upfront Cash: $800.0 million
Deal Type: Acquisition February 18, 2022
Details:
Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with GA. GT005 is designed as an AAV2-based, one-time investigational gene therapy for GA secondary to AMD.
Lead Product(s): GT005
Therapeutic Area: Ophthalmology Product Name: GT005
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $1,500.0 million Upfront Cash: $800.0 million
Deal Type: Acquisition December 22, 2021
Details:
Gyroscope plans to use proceeds from this investment to support funding of ongoing clinical trials of GT005 in geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Lead Product(s): GT005
Therapeutic Area: Ophthalmology Product Name: GT005
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Financing November 08, 2021
Details:
Proceeds from the financing to be used in continuing to advance Gyroscope's clinical program for its investigational gene therapy, GT005, as well as our earlier stage pipeline.
Lead Product(s): GT005
Therapeutic Area: Ophthalmology Product Name: GT005
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering May 07, 2021
Details:
Gyroscope plans to use proceeds from the financing to advance the clinical development of GT005, the company’s lead investigational gene therapy being evaluated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Lead Product(s): GT005
Therapeutic Area: Ophthalmology Product Name: GT005
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Forbion’s Growth Opportunities Fund
Deal Size: $148.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing March 26, 2021
Details:
GT005 is an investigational one-time AAV-based gene therapy that is designed to restore balance to an overactive complement system by increasing production of the Complement Factor I (CFI) protein, and is intended to slow the progression of GA that can lead to blindness.
Lead Product(s): GT005
Therapeutic Area: Ophthalmology Product Name: GT005
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
FOCUS is a Phase I/II open-label clinical trial that was initiated in January 2019. The trial is evaluating the safety and dose response of GT005 in people with GA secondary to dry AMD.
Lead Product(s): GT005
Therapeutic Area: Ophthalmology Product Name: GT005
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Details:
GT005 is an investigational one-time AAV-based gene therapy that is delivered under the retina and is intended to slow the progression of GA that can lead to blindness.
Lead Product(s): GT005
Therapeutic Area: Ophthalmology Product Name: GT005
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
First patient dosed in Phase II EXPLORE trial evaluating GT005 in people with geographic atrophy secondary to dry AMD with a mutation in the Complement Factor I gene.
Lead Product(s): GT005
Therapeutic Area: Ophthalmology Product Name: GT005
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
